CRIS Curis (CRIS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001108205
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
Curis insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CURIS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 87.7% of the 11,407 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KAITIN KENNETH I bought about $5.5K of CRIS on Mar 31, 2026, the largest insider purchase at the company on our record; 13 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 27, 2022.
- The trade is 4.8% of the 64,877 shares held after it.
- No other insider sold within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Dentzer James E sold about $9.5K of CRIS on Jan 31, 2022, the largest insider sale at the company on our record; 13 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.5% of the 67,971 shares held after it.
- No other insider sold within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Dentzer James E sold about $7.7K of CRIS on Jan 27, 2022, the largest insider sale at the company on our record; 13 funds added in the latest 13F quarter.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
-13.4% year over year
below 67% of Pharma & Biotech
Margin
-80.3% net margin
below 56% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
21.5% of the float short (float per yahoo 2026-10-27) · 1.9 days to cover · settled 2026-10-15
more than 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CRIS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-98.8%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CRIS: institutional holders (13F)
13F holdings, latest reported quarter
17,624,372 sh
$4.9M
3,802,329 sh
$2.0M
98,996 sh
$1.0M
1,978,876 sh
$1.0M
1,333,334 sh
$696.1K
Congress trades in CRIS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CRIS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CRIS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$66.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$50.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$10.0K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$1.6K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$112.6K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$5.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
1 active
2
Multi-phase
1 active
What changed recently
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in
2026-10-07 · Completion moved 2026-08 → 2027-07
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · James E. Dentzer
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.7M
$970.8K
$928.8K
-91%
n/a
2024
$2.0M
$860.6K
$1.1M
-72%
n/a
2023
$1.7M
$2.4M
$948.0K
+16%
n/a
2022
$3.0M
$2.3M
$1.1M
-7%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CRIS financials
Revenue growth
-13.4%
XBRL, annual
Net margin
-80.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CRIS
| FY Dec 2025 | $9.4M |
| FY Dec 2024 | $10.9M |
| FY Dec 2023 | $10.0M |
| FY Dec 2022 | $10.2M |
| FY Dec 2021 | $10.6M |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $1.1M |
| Sep 2025 | $3.2M |
| Jun 2025 | $2.7M |
| Mar 2025 | $2.4M |
| Dec 2024 | $3.3M |
| Sep 2024 | $2.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-490.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CRIS
| FY Dec 2025 | -80.3% |
| FY Dec 2024 | -397.8% |
| FY Dec 2023 | -473.0% |
| FY Dec 2022 | -557.7% |
| FY Dec 2021 | -426.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | +1,701% |
| Sep 2025 | -243.4% |
| Jun 2025 | -312.6% |
| Mar 2025 | -446.1% |
| Dec 2024 | -287.5% |
| Sep 2024 | -344.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$30.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CRIS
| FY Dec 2025 | -$27.2M |
| FY Dec 2024 | -$39.6M |
| FY Dec 2023 | -$38.4M |
| FY Dec 2022 | -$54.8M |
| FY Dec 2021 | -$37.6M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2021-09-30 (57 months older than the period end) plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity CRIS
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.43x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt CRIS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -5.24x |
| FY Dec 2023 | -4.52x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -4.33x |
| Jun 2025 | -4.14x |
| Mar 2025 | -4.64x |
| Dec 2024 | -5.24x |
| Sep 2024 | -4.76x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity CRIS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -634.7% |
| FY Dec 2023 | -143.2% |
| FY Dec 2022 | -82.6% |
| FY Dec 2021 | -41.0% |
| Jun 2026 | n/a |
| Mar 2026 | -693.9% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -2,951% |
| Dec 2024 | -634.7% |
| Sep 2024 | -436.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-87.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CRIS
| FY Dec 2025 | -24.8% |
| FY Dec 2024 | -73.2% |
| FY Dec 2023 | -50.9% |
| FY Dec 2022 | -41.8% |
| FY Dec 2021 | -24.8% |
| Jun 2026 | -87.8% |
| Mar 2026 | -61.3% |
| Dec 2025 | -24.8% |
| Sep 2025 | -104.3% |
| Jun 2025 | -97.7% |
| Mar 2025 | -83.1% |
| Dec 2024 | -73.2% |
| Sep 2024 | -68.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CRIS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-115.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CRIS
| FY Dec 2025 | -40.6% |
| FY Dec 2024 | -114.9% |
| FY Dec 2023 | -62.7% |
| FY Dec 2022 | -42.8% |
| FY Dec 2021 | -24.5% |
| Jun 2026 | -115.6% |
| Mar 2026 | -41.7% |
| Dec 2025 | -40.6% |
| Sep 2025 | -243.7% |
| Jun 2025 | -185.6% |
| Mar 2025 | -120.8% |
| Dec 2024 | -114.9% |
| Sep 2024 | -98.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CRIS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 3,808.00x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$4.3M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term 2021-09-30 (57 months older than the period end) plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value CRIS
| FY Dec 2025 | $250.9M |
| FY Dec 2024 | $505.7M |
| FY Dec 2023 | $1.5B |
| FY Dec 2022 | $21.2B |
| FY Dec 2021 | $174.4B |
| Jun 2026 | $400.3M |
| Mar 2026 | $424.8M |
| Dec 2025 | $250.9M |
| Sep 2025 | $412.9M |
| Jun 2025 | $482.7M |
| Mar 2025 | $343.4M |
| Dec 2024 | $505.7M |
| Sep 2024 | $632.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3,851%
TTM free cash flow over market value at close 2026-10-26
FCF yield CRIS
| FY Dec 2025 | -10.6% |
| FY Dec 2024 | -7.6% |
| FY Dec 2023 | -2.6% |
| FY Dec 2022 | -0.3% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -7.5% |
| Mar 2026 | -6.6% |
| Dec 2025 | -10.6% |
| Sep 2025 | -7.3% |
| Jun 2025 | -6.3% |
| Mar 2025 | -9.4% |
| Dec 2024 | -7.6% |
| Sep 2024 | -6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CRIS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $9.4M | $10.9M | $10.0M | $10.2M |
| Operating income | -$5.7M | -$44.5M | -$48.3M | -$53.0M |
| Net income | -$7.6M | -$43.4M | -$47.4M | -$56.7M |
| EPS (diluted) | -0.58 | -6.88 | -8.96 | -12.14 |
| Operating cash flow | -$27.2M | -$39.6M | -$38.4M | -$54.3M |
| Cash | $5.1M | $20.0M | $26.7M | $19.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
CRIS Stock Sonar score 5/7 axes
Find similar shapesCompareCRIS ranks highest on financial health (99th percentile) and growth (33rd), and lowest on risk and compliance (18th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
